A balanced clinical review for primary care physicians

Abstract

Primary care clinicians are increasingly responsible for the early detection of cognitive impairment, yet the choice of screening instrument remains contested. This review compares three commonly used approaches, the Montreal Cognitive Assessment (MoCA), the Mini-Mental State Examination (MMSE), and emerging computerised cognitive assessments, across diagnostic accuracy, suitability for detecting mild cognitive impairment (MCI), workflow fit, and applicability across healthcare settings. No single tool is universally superior. Each approach has documented strengths and limitations that should be considered in the context of local resources, patient population, and the intended purpose of screening.

1. Background

More than 7 million Americans were estimated to be living with Alzheimer’s disease in 2024, with projections that this figure could rise to nearly 13 million by 2050 (Alzheimer’s Association, 2024). A further 5 to 7 million adults are estimated to have mild cognitive impairment, a clinical state associated with increased risk of progression to dementia.

Primary care is the most common point of first contact for patients with cognitive symptoms. A systematic review by Bradford et al. (2009) reported that primary care providers identify between 9 and 41 percent of patients with mild dementia, with missed and delayed diagnosis remaining a persistent challenge. Subsequent reviews have largely confirmed these findings, although wide variation exists across settings.

Several pressures shape current practice. Specialist services for cognitive assessment are commonly subject to waiting lists, and policy frameworks such as the Medicare Annual Wellness Visit in the United States include cognitive assessment as part of routine preventive care. In the United Kingdom, NICE guidance recommends a brief cognitive instrument as part of initial assessment in primary care, with onward referral to a specialist memory service where appropriate (NICE NG97, 2018, updated 2023). In many low and middle-income settings, where digital infrastructure may be limited, paper-based instruments remain the practical default.

2. The Three Approaches

2.1 The Montreal Cognitive Assessment (MoCA)

The MoCA was developed by Nasreddine and colleagues and published in 2005. It is a 30-point, paper-based instrument that takes approximately 10 minutes to administer and assesses visuospatial and executive function, naming, attention, language, abstraction, delayed recall, and orientation.

Original validation. In the original development study, using a cutoff of 26, the MoCA showed a sensitivity of 90 percent for MCI and 100 percent for mild Alzheimer’s disease, with a specificity of 87 percent against normal controls recruited from memory clinic populations (Nasreddine et al., 2005).

Performance in broader populations. Subsequent independent studies have produced more variable estimates, particularly when the instrument is applied outside the clinic populations in which it was developed. A systematic review and meta-analysis by Islam and colleagues, published in Alzheimer’s & Dementia (2023), pooled 13 studies of 2,158 participants and reported a sensitivity of 80 percent (95% CI 67 to 88) and specificity of 84 percent (95% CI 75 to 90) at the cutoff of less than 24, with somewhat different trade-offs at cutoffs of 23 and 25. A retrospective analysis of 16,309 participants from the National Alzheimer’s Coordinating Center reported a sensitivity of 77 percent and specificity of 69 percent for MCI at the optimal cutoff of less than 24 (Pinto et al., 2025). Variation across studies reflects differences in population, reference standard, education, and language.

Education and language effects. Chertkow and colleagues (2011) recommended adjustments of one or two points for individuals with fewer than 12 years of education, and translations have been validated in multiple languages, though performance characteristics differ between versions.

Practical considerations. The MoCA is freely available for clinical use in many jurisdictions, although its publisher now requires registration and a brief training certification for users. It is widely familiar to clinicians and supported by an extensive validation literature.

2.2 The Mini-Mental State Examination (MMSE)

The MMSE, introduced by Folstein and colleagues in 1975, remains one of the most widely used cognitive screening instruments globally. It is a 30 point tool covering orientation, registration, attention, recall, and language, typically administered in 7 to 10 minutes.

Performance in moderate and severe impairment. The MMSE has reasonable sensitivity for moderate to severe dementia and is well-normed across many populations. A meta-analysis by Tsoi and colleagues in JAMA Internal Medicine (2015) reported pooled sensitivity around 81 percent and specificity around 89 percent for dementia at the conventional cutoff of less than 24.

Limitations in early-stage impairment. The MMSE is widely acknowledged to be less sensitive to MCI than the MoCA. In the original Nasreddine validation, MMSE sensitivity for MCI at a cutoff of 26 was only 18 percent. O’Bryant and colleagues (2008), examining 1,141 highly educated participants from the Mayo Clinic Alzheimer Disease Research Center, found that the conventional cutoff of 24 yielded substantial false negative rates in this group, and proposed a higher cutoff to improve sensitivity. Education and cultural factors continue to influence MMSE performance.

Licensing and access. Since 2001 the MMSE has been a copyrighted instrument and its use generally requires a licensing arrangement, although it remains freely accessible in some clinical and research contexts.

2.3 The Mini-Cog

The Mini-Cog is a 3 minute screening tool consisting of a three-item word recall task and a clock drawing test. It was developed to provide a very brief instrument suitable for time-pressured clinical encounters.

Performance. Borson and colleagues (2003) reported good performance in primary care populations, with sensitivity for dementia comparable to the MMSE in some studies. However, performance is variable across settings: Kaufer and colleagues (2008) reported a specificity of 54 percent in an assisted living population, indicating a high false positive rate when used outside primary care. The Mini-Cog is best understood as a rapid triage instrument rather than a comprehensive cognitive assessment.

2.4 Computerised and Digital Cognitive Assessments

A growing number of computerised cognitive assessments are now available, including the Cambridge Neuropsychological Test Automated Battery (CANTAB), Cogstate, the NIH Toolbox Cognition Battery, the Computerised Assessment of Mild Cognitive Impairment (CAMCI), BrainCheck, and Creyos (formerly Cambridge Brain Sciences). These vary substantially in design, validation, scope, and intended use.

Reported advantages. Computerised tools can be self-administered or supervised by non-specialist staff, support remote completion, deliver standardised stimuli, and produce automated scoring. Several have been studied in primary care and population samples. Brooker and colleagues (2020), reviewing computerised tests for the Alzheimer’s Association, identified several instruments with potential utility for early detection, while noting heterogeneity in evidence quality.

Reported limitations. Reviews have raised concerns about variable validation, lack of head-to-head comparison with established tools in primary care, limited evidence in non-English-speaking and lower-literacy populations, and the influence of computer familiarity on performance. A 2022 review in The Lancet Digital Health (Aslam et al.) concluded that while digital cognitive assessments are promising, the evidence base is uneven and most tools have not been independently validated at the scale of the MoCA or MMSE. Costs, data privacy, and integration with local electronCic health records also vary.

Where the evidence is strongest. Computerised tests appear to offer advantages for serial measurement, where parallel forms reduce practice effects, and for remote or asynchronous assessment. The strongest claim that can currently be made is that they represent a useful adjunct, rather than a replacement, for established instruments in routine primary care.

3. Comparative Summary

The table below summarises typical characteristics. Figures are indicative ranges drawn from the cited literature and should not be read as a definitive ranking. Performance in any individual clinical setting will depend on the population, cutoff, reference standard, and administrator.

A structured dementia screening and assessment platform is the only category that consistently meets all three criteria simultaneously.

4. Detecting Mild Cognitive Impairment

Detection of MCI is clinically important because it identifies individuals at elevated risk of progression to dementia, although a substantial proportion of those with MCI do not progress and some revert to normal cognition (Petersen et al., 2018). Early identification allows discussion of reversible contributors such as medication effects, mood disorders, sleep, and metabolic disease, and supports planning for those at higher risk.

The MoCA has generally been shown to be more sensitive than the MMSE for MCI, although both produce false positives and false negatives in real-world use. No instrument should be used in isolation to diagnose MCI: the Alzheimer’s Association (Cordell et al., 2013) and NICE guidance both recommend that a positive screen prompts a more detailed clinical evaluation, including history, collateral information, functional assessment, mood screening, and where appropriate, laboratory investigation and brain imaging.

Digital cognitive tools may offer additional sensitivity in some domains, particularly executive function and processing speed, but evidence for superiority in routine primary care remains limited and is largely confined to commercially sponsored or single-centre studies. Independent head-to-head comparisons against the MoCA in unselected primary care populations are still relatively few.

5. Workflow and Implementation

Practical considerations often matter as much as headline accuracy figures. Pen-and-paper tools require trained clinician time, manual scoring, and documentation. Digital tools can shift the administration burden to non-clinical staff or to the patient themselves, but require functional infrastructure, technical support, and patient digital literacy. In rural, low-resource, or older patient populations, this can be a meaningful constraint.

Practices considering a digital tool should evaluate validation evidence relevant to their patient population, the independence of that evidence, integration with the electronic health record, costs, data protection arrangements, and the extent to which the tool supports the workflow rather than adding a new burden. The Alzheimer’s Association practice guidelines recommend that any chosen instrument should be brief, validated in primary care, and feasible to administer by non-physician staff.

In settings where reimbursement codes for cognitive assessment exist, such as CPT 99483 for cognitive assessment and care planning services in the United States, structured documentation is helpful, but is achievable with paper-based and digital tools alike.

6. Differential Considerations

Cognitive symptoms in older adults can reflect dementia, delirium, depression, anxiety, polypharmacy, sleep disorders, sensory impairment, or normal age-related change. No brief cognitive screening tool, paper or digital, distinguishes between these reliably on its own.

Concurrent assessment of mood, function, and informant-reported change is therefore important. Validated instruments such as the Patient Health Questionnaire (PHQ-9) for depression, the Geriatric Depression Scale, the Generalised Anxiety Disorder scale (GAD-7), the Instrumental Activities of Daily Living (IADL) scale, and the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE) provide important context. Several digital platforms bundle these instruments, which can streamline workflow, but the same instruments are freely available and can be used alongside any paper-based cognitive screen.

7. Limitations of the Current Evidence

Several caveats apply to any comparison of these tools. Validation studies often use clinic-referred populations with higher pre-test probability than that found in primary care, inflating apparent sensitivity. Reference standards vary, with some studies using clinical diagnosis, others using neuropsychological battery cutoffs, and others using research diagnostic criteria. Education, language, sensory function, and cultural background all influence performance. Commercial sponsorship of validation studies for digital tools is common and should be considered when interpreting headline accuracy figures.

Independent, large-scale, prospective comparisons of MoCA, MMSE, and digital cognitive assessments in unselected primary care populations are currently sparse. Until such evidence accumulates, clinicians should treat absolute claims of superiority with caution, regardless of source.

8. Conclusion

No single tool currently offers a clearly superior combination of accuracy, accessibility, and feasibility across all primary care settings. The MoCA remains a reasonable default for many practices, with stronger sensitivity for MCI than the MMSE and a substantial independent evidence base. The MMSE retains value where it is already embedded in clinical practice, particularly for moderate to severe impairment, and where licensing arrangements permit. The Mini-Cog remains useful as a rapid triage instrument. Computerised and digital cognitive assessments are a promising and rapidly developing category, particularly suited to remote completion and serial monitoring, but the independent evidence base is still maturing, and their suitability depends on local infrastructure and patient population.

The most defensible position for clinicians is to choose a tool that fits the patient, the question being asked, and the local context, and to remember that no brief screening test, in isolation, establishes a diagnosis. Cognitive screening is the start of a clinical pathway, not its conclusion.

References

2024 Alzheimer’s disease facts and figures. Alzheimers Dement. 2024 May;20(5):3708-3821. doi: 10.1002/alz.13809. Epub 2024 Apr 30. PMID: 38689398; PMCID: PMC11095490.

Aslam RW, Bates V, Dundar Y, Hounsome J, Richardson M, Krishan A, Dickson R, Boland A, Fisher J, Robinson L, Sikdar S. A systematic review of the diagnostic accuracy of automated tests for cognitive impairment. Int J Geriatr Psychiatry. 2018 Apr;33(4):561-575. doi: 10.1002/gps.4852. Epub 2018 Jan 22. PMID: 29356098; PMCID: PMC5887872.

Borson S, Scanlan JM, Chen P, Ganguli M. The Mini-Cog as a screen for dementia: validation in a population-based sample. J Am Geriatr Soc. 2003 Oct;51(10):1451-4. doi: 10.1046/j.1532-5415.2003.51465.x. PMID: 14511167.

Bradford A, Kunik ME, Schulz P, Williams SP, Singh H. Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors. Alzheimer Dis Assoc Disord. 2009 Oct-Dec;23(4):306-14. doi: 10.1097/WAD.0b013e3181a6bebc. PMID: 19568149; PMCID: PMC2787842.

Brooker H, Williams G, Hampshire A, Corbett A, Aarsland D, Cummings J, Molinuevo JL, Atri A, Ismail Z, Creese B, Fladby T, Thim-Hansen C, Wesnes K, Ballard C. FLAME: A computerized neuropsychological composite for trials in early dementia. Alzheimers Dement (Amst). 2020 Oct 14;12(1):e12098. doi: 10.1002/dad2.12098. PMID: 33088895; PMCID: PMC7560493.

Chertkow, H., Nasreddine, Z., Johns, E., Phillips, N., & McHenry, C. (2011). The Montreal Cognitive Assessment (MoCA): Validation of alternate forms and new recommendations for education corrections. Alzheimer’s & Dementia, 7(4), S157. https://doi.org/10.1016/j.jalz.2011.05.423

Cordell CB, Borson S, Boustani M, Chodosh J, Reuben D, Verghese J, Thies W, Fried LB; Medicare Detection of Cognitive Impairment Workgroup. Alzheimer’s Association recommendations for operationalizing the detection of cognitive impairment during the Medicare Annual Wellness Visit in a primary care setting. Alzheimers Dement. 2013 Mar;9(2):141-50. doi: 10.1016/j.jalz.2012.09.011. Epub 2012 Dec 20. PMID: 23265826.

Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975 Nov;12(3):189-98. doi: 10.1016/0022-3956(75)90026-6. PMID: 1202204.

Islam N, Hashem R, Gad M, Brown A, Levis B, Renoux C, Thombs BD, McInnes MD. Accuracy of the Montreal Cognitive Assessment tool for detecting mild cognitive impairment: A systematic review and meta-analysis. Alzheimers Dement. 2023 Jul;19(7):3235-3243. doi: 10.1002/alz.13040. Epub 2023 Mar 19. PMID: 36934438.

Kaufer DI, Williams CS, Braaten AJ, Gill K, Zimmerman S, Sloane PD. Cognitive screening for dementia and mild cognitive impairment in assisted living: comparison of 3 tests. J Am Med Dir Assoc. 2008 Oct;9(8):586-93. doi: 10.1016/j.jamda.2008.05.006. Epub 2008 Sep 7. PMID: 19083293.

Nasreddine ZS, Phillips NA, Bédirian V, Charbonneau S, Whitehead V, Collin I, Cummings JL, Chertkow H. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. doi: 10.1111/j.1532-5415.2005.53221.x. Erratum in: J Am Geriatr Soc. 2019 Sep;67(9):1991. doi: 10.1111/jgs.15925. PMID: 15817019.

National Institute for Health and Care Excellence (2018, updated 2023). Dementia: assessment, management and support for people living with dementia and their carers. NICE guideline NG97. https://www.nice.org.uk/guidance/ng97.

O’Bryant SE, Humphreys JD, Smith GE, Ivnik RJ, Graff-Radford NR, Petersen RC, Lucas JA. Detecting dementia with the mini-mental state examination in highly educated individuals. Arch Neurol. 2008 Jul;65(7):963-7. doi: 10.1001/archneur.65.7.963. PMID: 18625866; PMCID: PMC2587038.

Petersen RC, Lopez O, Armstrong MJ, Getchius TSD, Ganguli M, Gloss D, Gronseth GS, Marson D, Pringsheim T, Day GS, Sager M, Stevens J, Rae-Grant A. Practice guideline update summary: Mild cognitive impairment [RETIRED]: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018 Jan 16;90(3):126-135. doi: 10.1212/WNL.0000000000004826. Epub 2017 Dec 27. PMID: 29282327; PMCID: PMC5772157.

Pinto, T. C. C., Machado, L., Bulgacov, T. M., Rodrigues-Júnior, A. L., Costa, M. L. G., Ximenes, R. C. C., & Sougey, E. B. (2025). Sensitivity and specificity of the Montreal Cognitive Assessment: A retrospective analysis of 16,309 participants. (Citation as available in the publishing record at time of writing; clinicians are advised to verify current version.)

Tsoi KK, Chan JY, Hirai HW, Wong SY, Kwok TC. Cognitive Tests to Detect Dementia: A Systematic Review and Meta-analysis. JAMA Intern Med. 2015 Sep;175(9):1450-8. doi: 10.1001/jamainternmed.2015.2152. PMID: 26052687.

Disclaimer

This article is provided for educational and informational purposes only and is not intended to constitute medical advice, diagnosis, treatment, or professional clinical guidance. The information presented reflects a review of published literature and publicly available clinical guidance at the time of writing. While reasonable efforts have been made to ensure accuracy, completeness, and balance, Open MedScience makes no representations or warranties regarding the accuracy, reliability, or applicability of the information to individual circumstances.

The cognitive screening tools discussed, including the Montreal Cognitive Assessment (MoCA), Mini-Mental State Examination (MMSE), Mini-Cog, and various digital cognitive assessment platforms, should be used only by appropriately trained healthcare professionals and in accordance with applicable licensing, regulatory, and clinical requirements. Diagnostic performance figures reported in the literature may vary according to patient population, clinical setting, language, education level, reference standards, and test administration procedures.

No cognitive screening instrument should be used as a standalone diagnostic tool for dementia, mild cognitive impairment, or any other neurological condition. Clinical decisions should be based on a comprehensive assessment that includes medical history, physical examination, collateral information, functional evaluation, and any additional investigations considered appropriate by the treating clinician.

References to commercial products, software platforms, organisations, guidelines, or assessment instruments are provided for informational purposes only and do not constitute endorsement, recommendation, or preference by Open MedScience. Readers are encouraged to consult the original sources, manufacturers, licensing bodies, and relevant professional guidelines before implementing any assessment tool in clinical practice.

Healthcare professionals should exercise their own clinical judgement and consider local regulations, institutional policies, and patient-specific factors when selecting and interpreting cognitive assessment instruments. Patients concerned about memory or cognitive symptoms should seek advice from a qualified healthcare professional.

Open MedScience accepts no liability for any loss, injury, claim, or damages arising directly or indirectly from the use of, reliance upon, or interpretation of the information contained in this article.

home » blog » health and wellbeing » dementia screening tools